VR Adviser »

Ocular Therapeutix shares owned by VR Adviser

Quarter-by-quarter ownership of Ocular Therapeutix (OCUL) shares owned by VR Adviser from 13F filings

Historical chart of VR Adviser investment in Ocular Therapeutix

Tip: Access up to 7 years of quarterly data

All positions including Ocular Therapeutix held by VR Adviser consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ocular Therapeutix by VR Adviser

Quarter filed Position value Share count Share price at filing
2023-12-31 $35M 7.8M 4.46

More positions owned by VR Adviser

Rayzebio
Apogee Therapeutics (APGE)
Pharvaris N V (PHVS)
Miragen Therapeutics (VRDN)
4d Molecular Therapeutics In (FDMT)
Merus N V (MRUS)
Cabaletta Bio (CABA)
Spyre Therapeutics Com New (SYRE)
Kalvista Pharmaceuticals (KALV)
Enliven Therapeutics (ELVN)
Ocular Therapeutix (OCUL)
Hillevax (HLVX)
Ambrx Biopharma
Terns Pharmaceuticals (TERN)
Dyne Therapeutics (DYN)

View all positions for VR Adviser

Top funds holding Ocular Therapeutix

VR Adviser
Summer Road
Opaleye Management
Vanguard Group
Franklin Resources
Logos Global Management
Citadel Advisors
Deltec Asset Management
Millennium Management
Dr. Jeffrey R. Jay, M.D.
Banco Santander
Artia Global Partners
D. E. Shaw & Co
Essex Investment Management
Bank of New York Mellon

View all funds holding Ocular Therapeutix